The Administrative Core will provide for the administration of the Lymphoma SPORE including administrative and budget support for all the SPORE investigators. In addition, this Core will provide communication with the National SPORE Program staff, coordination with the City of Hope Comprehensive Cancer Center Administrative Office, preparation of progress reports, management of financial and reporting obligations, organization of the weekly research meetings of the basic science and clinical research staff, coordination of intra- and inter-institutional and inter-SPORE projects, as well as organizing the attendance and presentations at the annual City of Hope Lymphoma SPORE retreat and SPORE workshops at the National Cancer Institute. Importantly, this core will be responsible for the oversight of the Developmental Research and Career Development Programs in the City of Hope Lymphoma SPORE. Publications, grant submissions and INDs will also be coordinated and supported through this Core. In addition, the Administrative Core will arrange the Executive and Steering Committee meetings that will review the progress of the work and organize the annual External Advisory Board meetings.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA107399-09
Application #
8731635
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
9
Fiscal Year
2014
Total Cost
Indirect Cost
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
City
Duarte
State
CA
Country
United States
Zip Code
91010
Herrera, Alex F; Rodig, Scott J; Song, Joo Y et al. (2018) Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant 24:514-520
Budde, Lihua E; Wu, David; Martin, Daniel B et al. (2018) Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. Br J Haematol 183:601-607
Herrera, A F; Palmer, J; Martin, P et al. (2018) Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Ann Oncol 29:724-730
Zhao, Xingli; Zhang, Zhuoran; Moreira, Dayson et al. (2018) B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors. Mol Ther 26:695-707
Adamus, Tomasz; Kortylewski, Marcin (2018) The revival of CpG oligonucleotide-based cancer immunotherapies. Contemp Oncol (Pozn) 22:56-60
Herrera, Alex F; Moskowitz, Alison J; Bartlett, Nancy L et al. (2018) Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood 131:1183-1194
Chen, Robert W; Palmer, Joycelynne M; Tomassetti, Sarah et al. (2018) Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. J Hematol Oncol 11:87
Wang, Xiuli; Walter, Miriam; Urak, Ryan et al. (2018) Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma. Clin Cancer Res 24:106-119
Jiang, Nenggang; Chen, Christopher; Gong, Qiang et al. (2017) Flow cytometric sorting coupled with exon capture sequencing identifies somatic mutations in archival lymphoma tissues. Lab Invest 97:1364-1374
Herrera, Alex F; Armand, Philippe (2017) Minimal Residual Disease Assessment in Lymphoma: Methods and Applications. J Clin Oncol 35:3877-3887

Showing the most recent 10 out of 97 publications